CIViC Evidence

Evidence Items are the central building block of the Clinical Interpretation of Variants in Cancer (CIViC) knowledgebase. The clinical Evidence Item is a piece of information that has been manually curated from trustable medical literature about a Variant or genomic ‘event’ that has implications in cancer Predisposition, Diagnosis (aka molecular classification), Prognosis, Predictive response to therapy, Oncogenicity or protein Function. For example, an Evidence Item might describe a line of evidence supporting the notion that tumors with a somatic BRAF V600 mutation generally respond well to the drug dabrafenib. A Variant may be a single nucleotide substitution, a small insertion or deletion, an RNA gene fusion, a chromosomal rearrangement, an RNA expression pattern (e.g. over-expression), etc. Each clinical Evidence statement corresponds to a single citable Source (a publication or conference abstract).

证据项是癌症变体临床解释（CIViC）知识库的核心构建模块。临床证据项是一段经过人工精心筛选的信息，源自可靠的医学文献，涉及对癌症易感性、诊断（亦称分子分类）、预后、对治疗预测性反应、肿瘤发生学或蛋白质功能具有影响变异或基因组‘事件’。例如，一个证据项可能描述支持以下观点的证据链：携带体细胞BRAF V600突变的肿瘤通常对达拉非尼药物反应良好。变异可能包括单个核苷酸替换、小段插入或删除、RNA基因融合、染色体重排、RNA表达模式（例如，过表达）等。每个临床证据陈述均对应一个可引用的来源（出版物或会议摘要）。